FDA urges consumers to avoid sexual-enhancement drinks

Jan 03, 2011 By Eryn Brown

The Food and Drug Administration advised consumers on Thursday not to buy or use two drinks sold as supplements for sexual enhancement.

The products, Rock Hard Extreme and Passion Coffee, are sold on websites and possibly in retail outlets, the agency said. Laboratory analysis indicated that both contain sulfoaildenafil, an active pharmaceutical ingredient that is similar to sildenafil, the active ingredient in Viagra.

Sulfoaildenafil could interact with that include nitrates, the FDA warned, lowering blood pressure to "dangerous levels." Nitrate-containing drugs are often prescribed for men with diabetes, or heart disease.

The warning arrives barely two weeks after a Dec. 15 sent a warning letter to dietary supplement manufacturers in which the FDA said it would crack down on illegal supplements.

"We want consumers to be aware that there are products masquerading as that pose significant dangers," FDA Principal Deputy Commissioner Dr. Joshua Sharfstein said at the time.

Sharfstein told reporters that the FDA was concerned primarily with three types of supplements. One class is weight-loss products with active ingredients such as sibutramine, found in the drug Meridia, which was recently withdrawn from the market because of increased risk of heart attack and stroke. The other two are body-building products that contain or "steroid analogs," which can cause and increase the risk for heart attack, stroke and death; and sexual-enhancement products such as Rock Hard Extreme and Passion Coffee.

Sharfstein said that the products are poorly labeled, so consumers do not know what they are really buying.

Lawful dietary supplements, according to the FDA, are intended only as "an addition to a standard diet."

"If you have a drug product in it, it's not a supplement," said Judy Blatman, spokeswoman for the Council for Responsible Nutrition, an industry trade organization. "We're extremely supportive ot the FDA's actions to warn consumers about products that are masquerading as supplements. ... they're illegal."

Blatman said her organization would like the FDA to get even more aggressive. "We're hoping this will put a chill on companies who are doing this," she said.

In an e-mail to the Los Angeles Times, FDA spokesperson Siobhan DeLancey said that the agency had found nearly 300 such "tainted products" among dietary supplements it has examined. She did not specify how many of those were sexual-enhancement products.

DeLancey also said that the FDA had received reports of fatalities in people using illegal sexual-enhancement products.

The FDA advised consumers to stop using Rock Hard Extreme and Passion Coffee immediately, and to throw them away. It encouraged people who had experienced side effects from either drink to notify their doctor.

Explore further: FDA approves new drug for rare genetic disease

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA cracks down on illegal supplements

Dec 15, 2010

(AP) -- The Food and Drug Administration is cracking down on manufacturers of certain weight loss, body building and sexual enhancement supplements that contain potentially dangerous ingredients.

FDA seizes sexual enhancement products

Apr 10, 2008

The U.S. Food and Drug Administration announced the seizure by U.S. marshals of more than 14,000 units of Shangai- and Naturale-brand diet supplements.

FDA issues supplement rules

Jun 23, 2007

The U.S. Food and Drug Administration has issued new government standards for the manufacture of vitamins and dietary supplements.

FDA recalls Axcil and Desirin

Sep 24, 2007

The U.S. Food and Drug Administration announced the recall of two sexual enhancement products -- Axcil and Desirin -- because of undeclared, ingredients.

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

21 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0